Literature DB >> 22084166

Induction of vascular endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway.

Ana Markovic1, Karen L MacKenzie, Richard B Lock.   

Abstract

Human leukemia cells secrete VEGF, which can act in a paracrine manner within the bone marrow microenvironment to promote leukemia cell survival and proliferation. The FLT-3 receptor tyrosine kinase plays an essential role in regulating normal hematopoiesis, but its constitutive activation via mutation in acute leukemias is generally associated with poor outcome. The aim of this study was to investigate interactions between the FLT-3 and VEGF signaling pathways in acute leukemia using cell lines and ex vivo cultures of pediatric acute lymphoblastic leukemia cells following expansion of direct patient explants in immunodeficient mice. Different xenograft lines exhibited variable cell surface FLT-3 expression, as well as basal and FLT-3 ligand-induced VEGF secretion, whereas the MV4;11 cell line, which expresses constitutively active FLT-3, secreted high levels of VEGF. The FLT-3 inhibitor, SU11657, significantly reduced VEGF secretion in three of six xenograft lines and MV4;11 cells, in conjunction with inhibition of FLT-3 tyrosine phosphorylation. Moreover, exposure of xenograft cells to the FLT-3-blocking antibody, D43, also reduced VEGF secretion to basal levels and decreased FLT-3 tyrosine phosphorylation. In terms of downstream signaling, SU11657 and D43 both caused dephosphorylation of extracellular signal-regulated kinase 1/2, with no changes in AKT or STAT5 phosphorylation. Finally, partial knockdown of FLT-3 expression by short interfering RNA also resulted in inhibition of VEGF secretion. These results indicate that FLT-3 signaling plays a central role in the regulation of VEGF secretion and that inhibition of the FLT-3/VEGF pathway may disrupt paracrine signaling between leukemia cells and the bone marrow microenvironment. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22084166     DOI: 10.1158/1535-7163.MCT-11-0503

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  5 in total

1.  Molecular effects of genistein, as a potential anticancer agent, on CXCR-4 and VEGF pathway in acute lymphoblastic leukemia.

Authors:  Mohsen Shahmoradi; Fatemeh Banisharif-Dehkordi; Mahnoush Kouhihabibidehkordi; Mahdi GhatrehSamani; Mohammad-Saied Jami; Hedayatollah Shirzad; Batoul Pourgheysari
Journal:  Mol Biol Rep       Date:  2022-05-24       Impact factor: 2.742

Review 2.  Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies.

Authors:  Soumit K Basu; Scot C Remick; Manish Monga; Laura F Gibson
Journal:  Clin Exp Metastasis       Date:  2013-12-05       Impact factor: 5.150

3.  Transcriptomic responses provide a new mechanistic basis for the chemopreventive effects of folic acid and tributyrin in rat liver carcinogenesis.

Authors:  Aline H Guariento; Kelly S Furtado; Aline de Conti; Adriana Campos; Eduardo Purgatto; Jéssica Carrilho; Elvira Maria Guerra Shinohara; Volodymyr Tryndyak; Tao Han; James C Fuscoe; Sharon A Ross; Frederick A Beland; Igor P Pogribny; Fernando S Moreno
Journal:  Int J Cancer       Date:  2014-02-22       Impact factor: 7.396

4.  Flt3 Regulation in the Mononuclear Phagocyte System Promotes Ocular Neovascularization.

Authors:  Yushuo Gao; Yisheng Zhong; Yanji Zhu; Anna M Demetriades; Yujuan Cai; Jikui Shen; Qing Lu; Xi Shen; Bing Xie
Journal:  J Ophthalmol       Date:  2018-05-03       Impact factor: 1.909

Review 5.  Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.

Authors:  Kelly L Harris; Meagan B Myers; Karen L McKim; Rosalie K Elespuru; Barbara L Parsons
Journal:  Environ Mol Mutagen       Date:  2019-10-06       Impact factor: 3.216

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.